Lu sur publilmed http://www.ncbi.nlm.nih.gov/pubmed/26802912
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Rappel : l'Azathioprine est connu sous les noms d'IMUREL et d'IMURAN
Remission and relapse of myasthenia gravis on long-term azathioprine: An ambispective study.
Gupta A1, Goyal V1, Srivastava AK1, Shukla G1, Behari M1.
1Department of Neurology, Cardiothoracic and Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, 110029, India.
Azathioprine (AZA) is commonly used in Myasthenia Gravis (MG).Treatment may be prolonged, entailing significant risks and avoidable costs.
We reviewed remission and relapse and side effect profiles in MG patients on AZA treatment and after tapering off.
We conducted an ambispective study and analyzed remission, relapse rates, and side effect profiles in 117 MG patients on AZA.
Thirty-nine patients (33.3%) achieved remission, and 36(30.8%) achieved complete stable remission(CSR) with a 33% relapse rate. No AZA side effects were seen in 95(81%) patients. Only duration of disease more than 10 years (OR 9.5, 95% CI 2.4 - 36.9, P= 0.001) was significantly associated with remission.
AZA is well tolerated by MG patients, and about 30% go into CSR on long-term AZA. This article is protected by copyright. All rights reserved.